Mice Model Market (Product Type: Transgenic Mice Model, Hybrid/Congenic Mice Model, Knockout Mice Model, Carcinogen-induced & Spontaneous Mice Model, Outbred Mice Model, Inbred Mice Model, Transplantation Mice Model, and Conditioned/Surgically Modified Mice Model; Specialty: Immunology, Central Nervous System [CNS], Oncology, Cardiovascular, Diabetes, and Metabolism & Regulation; and Service: Breeding & Rederivation Services, Cryopreservation & Cryorecovery Services, Quarantine Services, Genetic Testing Services, Model In-licensing Services, In Vivo & In Vitro Pharmacology Services, Genetically Engineered Model Services, and Other Services [Surgical and Line Rescue]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Mice Model Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Mice Model Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Industry Developments

    5.2. Overview of Mice Model Market

    5.3. Technological Advancements

    5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

6. Global Mice Model Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2017–2030

        6.3.1. Transgenic Mice Model

        6.3.2. Hybrid/Congenic Mice Model

        6.3.3. Knockout Mice Model

        6.3.4. Carcinogen-induced & Spontaneous Mice Model

        6.3.5. Outbred Mice Model

        6.3.6. Inbred Mice Model

        6.3.7. Transplantation Mice Model

        6.3.8. Conditioned/Surgically Modified Mice Model

    6.4. Market Attractiveness Analysis, by Type

7. Global Mice Model Market Analysis and Forecast, by Specialty

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Specialty, 2017–2030

        7.3.1. Immunology

        7.3.2. Central Nervous System (CNS)

        7.3.3. Oncology

        7.3.4. Cardiovascular

        7.3.5. Diabetes

        7.3.6. Metabolism & Regulation

    7.4. Market Attractiveness Analysis, by Specialty

8. Global Mice Model Market Analysis and Forecast, by Services

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Services, 2017–2030

        8.3.1. Breeding & Rederivation Services

        8.3.2. Cryopreservation & Cryorecovery Services

        8.3.3. Quarantine Services

        8.3.4. Genetic Testing Services

        8.3.5. Model In-licensing Services

        8.3.6. In Vivo & In Vitro Pharmacology Services

        8.3.7. Genetically Engineered Model Services

        8.3.8. Other Services (surgical and line rescue)

    8.4. Market Attractiveness Analysis, by Services

9. Global Mice Model Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Country/Region

10. North America Mice Model Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017–2030

        10.2.1. Transgenic Mice Model

        10.2.2. Hybrid/Congenic Mice Model

        10.2.3. Knockout Mice Model

        10.2.4. Carcinogen-induced & Spontaneous Mice Model

        10.2.5. Outbred Mice Model

        10.2.6. Inbred Mice Model

        10.2.7. Transplantation Mice Model

        10.2.8. Conditioned/Surgically Modified Mice Model

    10.3. Market Value Forecast, by Specialty, 2017–2030

        10.3.1. Immunology

        10.3.2. Central Nervous System (CNS)

        10.3.3. Oncology

        10.3.4. Cardiovascular

        10.3.5. Diabetes

        10.3.6. Metabolism & Regulation

    10.4. Market Value Forecast, by Services, 2017–2030

        10.4.1. Breeding & Rederivation Services

        10.4.2. Cryopreservation & Cryorecovery Services

        10.4.3. Quarantine Services

        10.4.4. Genetic Testing Services

        10.4.5. Model In-licensing Services

        10.4.6. In Vivo & In Vitro Pharmacology Services

        10.4.7. Genetically Engineered Model Services

        10.4.8. Other Services (surgical and line rescue)

    10.5. Market Value Forecast, by Country, 2017–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Specialty

        10.6.3. By Services

        10.6.4. By Country

11. Europe Mice Model Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017–2030

        11.2.1. Transgenic Mice Model

        11.2.2. Hybrid/Congenic Mice Model

        11.2.3. Knockout Mice Model

        11.2.4. Carcinogen-induced & Spontaneous Mice Model

        11.2.5. Outbred Mice Model

        11.2.6. Inbred Mice Model

        11.2.7. Transplantation Mice Model

        11.2.8. Conditioned/Surgically Modified Mice Model

    11.3. Market Value Forecast, by Specialty, 2017–2030

        11.3.1. Immunology

        11.3.2. Central Nervous System (CNS)

        11.3.3. Oncology

        11.3.4. Cardiovascular

        11.3.5. Diabetes

        11.3.6. Metabolism & Regulation

    11.4. Market Value Forecast, by Services, 2017–2030

        11.4.1. Breeding & Rederivation Services

        11.4.2. Cryopreservation & Cryorecovery Services

        11.4.3. Quarantine Services

        11.4.4. Genetic Testing Services

        11.4.5. Model In-licensing Services

        11.4.6. In Vivo & In Vitro Pharmacology Services

        11.4.7. Genetically Engineered Model Services

        11.4.8. Other Services (surgical and line rescue)

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Specialty

        11.6.3. By Services

        11.6.4. By Country/Sub-region

12. Asia Pacific Mice Model Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017–2030

        12.2.1. Transgenic Mice Model

        12.2.2. Hybrid/Congenic Mice Model

        12.2.3. Knockout Mice Model

        12.2.4. Carcinogen-induced & Spontaneous Mice Model

        12.2.5. Outbred Mice Model

        12.2.6. Inbred Mice Model

        12.2.7. Transplantation Mice Model

        12.2.8. Conditioned/Surgically Modified Mice Model

    12.3. Market Value Forecast, by Specialty, 2017–2030

        12.3.1. Immunology

        12.3.2. Central Nervous System (CNS)

        12.3.3. Oncology

        12.3.4. Cardiovascular

        12.3.5. Diabetes

        12.3.6. Metabolism & Regulation

    12.4. Market Value Forecast, by Services, 2017–2030

        12.4.1. Breeding & Rederivation Services

        12.4.2. Cryopreservation & Cryorecovery Services

        12.4.3. Quarantine Services

        12.4.4. Genetic Testing Services

        12.4.5. Model In-licensing Services

        12.4.6. In Vivo & In Vitro Pharmacology Services

        12.4.7. Genetically Engineered Model Services

        12.4.8. Other Services (surgical and line rescue)

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Specialty

        12.6.3. By Services

        12.6.4. By Country/Sub-region

13. Latin America Mice Model Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type , 2017–2030

        13.2.1. Transgenic Mice Model

        13.2.2. Hybrid/Congenic Mice Model

        13.2.3. Knockout Mice Model

        13.2.4. Carcinogen-induced & Spontaneous Mice Model

        13.2.5. Outbred Mice Model

        13.2.6. Inbred Mice Model

        13.2.7. Transplantation Mice Model

        13.2.8. Conditioned/Surgically Modified Mice Model

    13.3. Market Value Forecast, by Specialty, 2017–2030

        13.3.1. Immunology

        13.3.2. Central Nervous System (CNS)

        13.3.3. Oncology

        13.3.4. Cardiovascular

        13.3.5. Diabetes

        13.3.6. Metabolism & Regulation

    13.4. Market Value Forecast, by Services, 2017–2030

        13.4.1. Breeding & Rederivation Services

        13.4.2. Cryopreservation & Cryorecovery Services

        13.4.3. Quarantine Services

        13.4.4. Genetic Testing Services

        13.4.5. Model In-licensing Services

        13.4.6. In Vivo & In Vitro Pharmacology Services

        13.4.7. Genetically Engineered Model Services

        13.4.8. Other Services (surgical and line rescue)

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Specialty

        13.6.3. By Services

        13.6.4. By Country/Sub-region

14. Middle East & Africa Mice Model Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Type, 2017–2030

        14.2.1. Transgenic Mice Model

        14.2.2. Hybrid/Congenic Mice Model

        14.2.3. Knockout Mice Model

        14.2.4. Carcinogen-induced & Spontaneous Mice Model

        14.2.5. Outbred Mice Model

        14.2.6. Inbred Mice Model

        14.2.7. Transplantation Mice Model

        14.2.8. Conditioned/Surgically Modified Mice Model

    14.3. Market Value Forecast, by Specialty, 2017–2030

        14.3.1. Immunology

        14.3.2. Central Nervous System (CNS)

        14.3.3. Oncology

        14.3.4. Cardiovascular

        14.3.5. Diabetes

        14.3.6. Metabolism & Regulation

    14.4. Market Value Forecast, by Services, 2017–2030

        14.4.1. Breeding & Rederivation Services

        14.4.2. Cryopreservation & Cryorecovery Services

        14.4.3. Quarantine Services

        14.4.4. Genetic Testing Services

        14.4.5. Model In-licensing Services

        14.4.6. In Vivo & In Vitro Pharmacology Services

        14.4.7. Genetically Engineered Model Services

        14.4.8. Other Services (surgical and line rescue)

    14.5. Market Value Forecast, by Country, 2017–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Specialty

        14.6.3. By Services

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Company Profiles

        15.2.1. Charles River Laboratories International, Inc.

            15.2.1.1. Company Overview

            15.2.1.2. Financial Overview

            15.2.1.3. Product Portfolio

            15.2.1.4. Business Strategies

            15.2.1.5. Recent Developments

        15.2.2. Crescendo Biologics Limited

            15.2.2.1. Company Overview

            15.2.2.2. Financial Overview

            15.2.2.3. Product Portfolio

            15.2.2.4. Business Strategies

            15.2.2.5. Recent Developments

        15.2.3. Deltagen, Inc.

            15.2.3.1. Company Overview

            15.2.3.2. Financial Overview

            15.2.3.3. Product Portfolio

            15.2.3.4. Business Strategies

            15.2.3.5. Recent Developments

        15.2.4. genOway S.A.

            15.2.4.1. Company Overview

            15.2.4.2. Financial Overview

            15.2.4.3. Product Portfolio

            15.2.4.4. Business Strategies

            15.2.4.5. Recent Developments

        15.2.5. Harbour Antibodies BV

            15.2.5.1. Company Overview

            15.2.5.2. Financial Overview

            15.2.5.3. Product Portfolio

            15.2.5.4. Business Strategies

            15.2.5.5. Recent Developments

        15.2.6. Harlan Laboratories, Inc.

            15.2.6.1. Company Overview

            15.2.6.2. Financial Overview

            15.2.6.3. Product Portfolio

            15.2.6.4. Business Strategies

            15.2.6.5. Recent Developments

        15.2.7. ImmunoGenes AG

            15.2.7.1. Company Overview

            15.2.7.2. Financial Overview

            15.2.7.3. Product Portfolio

            15.2.7.4. Business Strategies

            15.2.7.5. Recent Developments

        15.2.8. The Jackson Laboratory

            15.2.8.1. Company Overview

            15.2.8.2. Financial Overview

            15.2.8.3. Product Portfolio

            15.2.8.4. Business Strategies

            15.2.8.5. Recent Developments

        15.2.9. Taconic Biosciences, Inc.

            15.2.9.1. Company Overview

            15.2.9.2. Financial Overview

            15.2.9.3. Product Portfolio

            15.2.9.4. Business Strategies

            15.2.9.5. Recent Developments

        15.2.10. TransGenic, Inc.

            15.2.10.1. Company Overview

            15.2.10.2. Financial Overview

            15.2.10.3. Product Portfolio

            15.2.10.4. Business Strategies

            15.2.10.5. Recent Developments